NCT05558124 2026-02-27
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
Clinical Trials
6 trialsNCT04915612 2026-02-20
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Completed
NCT06448013 2025-12-15
A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03900949 2025-10-28
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT05716009 2025-05-06
GO-TAG
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT04070768 2025-05-04
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
Big Ten Cancer Research Consortium
Phase 1 Completed